Nutritional Supplements and Nitric Oxide Bioactivity

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status

Completed

Conditions

Postprandial Metabolism
Nitrate / Nitrite
Nitric Oxide
Vascular Function
L-Arginine

Treatments

Dietary Supplement: Placebo
Dietary Supplement: L-Arginine
Dietary Supplement: Nitrate / Nitrite

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03625596
METC 18-3-010

Details and patient eligibility

About

Obese people have a disturbed postprandial metabolism and thereby a decreased postprandial vascular function. Nitric oxide plays an important role in the postprandial vascular function. Multiple studies already focused on various nutritional compounds to improve the postprandial vascular function by increasing the nitric oxide bioactivity. However, the vast majority of the trials has been performed with relatively high doses of the individual components, which are problematic to convert into daily food measures, thereby preventing translation of these findings. Well-designed trails studying the effect of feasible amounts of nutritional supplements on the bioactivity of nitric oxide and vascular function are missing.

Enrollment

20 patients

Sex

Male

Ages

40 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Men
  • Aged between 40-70 years
  • Waist circumference ≥ 102
  • Fasting plasma glucose < 7.0 mmol/L
  • Fasting serum total cholesterol < 8.0 mmol/L
  • Stable body weight (weight gain or loss < 3 kg in the past three months)
  • Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
  • No difficult venipuncture as evidenced during the screening visit
  • No current smoker
  • No diabetic patients
  • No familial hypercholesterolemia
  • No abuse of drugs
  • No more than 3 alcoholic consumptions per day
  • No use of medication known to treat blood pressure, lipid or glucose metabolism
  • No use of an investigational product within another biomedical intervention trial within the previous 1-month
  • No severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
  • No active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
  • Willingness to give up the use of antibacterial mouth wash or antibacterial toothpaste, chewing-gum and tongue- scraping on the morning of each experimental test day

Exclusion criteria

  • Women
  • Fasting plasma glucose ≥ 7.0 mmol/L
  • Fasting serum total cholesterol ≥ 8.0 mmol/L
  • Current smoker, or smoking cessation <12 months
  • Diabetic patients
  • Familial hypercholesterolemia
  • Abuse of drugs
  • More than 3 alcoholic consumptions per day
  • Unstable body weight (weight gain or loss > 3 kg in the past three months)
  • Use medication known to treat blood pressure, lipid or glucose metabolism
  • Use of an investigational product within another biomedical intervention trial within the previous 1-month
  • Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
  • Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
  • Not willing to give up being a blood donor from 8 weeks before the start of the study, during the study or for 4 weeks after completion of the study
  • Not or difficult to venipuncture as evidenced during the screening visit

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

20 participants in 5 patient groups, including a placebo group

High L-arginine
Active Comparator group
Description:
During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
Treatment:
Dietary Supplement: L-Arginine
Medium L-arginine + Nitrate / Nitrite
Experimental group
Description:
During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
Treatment:
Dietary Supplement: Nitrate / Nitrite
Dietary Supplement: L-Arginine
Low L-arginine + Nitrate / Nitrite
Experimental group
Description:
During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
Treatment:
Dietary Supplement: Nitrate / Nitrite
Dietary Supplement: L-Arginine
Nitrate / Nitrite
Experimental group
Description:
During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
Treatment:
Dietary Supplement: Nitrate / Nitrite
Placebo
Placebo Comparator group
Description:
During this experimental day, men will receive a high-fat shake without supplement.
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems